Stevanato (STVN)

• Market cap: $5.61B
• 1 day: -3.66%
• 5 days: -10.49%
• 1 month: 12.53%
• 3 months: 6.75%
• 6 months: 17.49%
• Year to date: -22.62%
• 1 year: -27.14%
• 5 years: 4.52%
• 10 years: 4.52%

About: Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Employees: 5,635

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

59% more call options, than puts

Call options by funds: $54K | Put options by funds: $34K

13% more capital invested

Capital invested by funds: $961M [Q2] → $1.08B (+$121M) [Q3]

3.5% more ownership

Funds ownership: 105.87% [Q2] → 109.37% (+3.5%) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 48

2% less funds holding

Funds holding: 131 [Q2] → 128 (-3) [Q3]

13% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 24

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $23 12% upside
• Avg. target: $26 25% upside
• High target: $28 36% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target	26% upside $26	Buy Maintained	13 Dec 2024
Wolfe Research Doug Schenkel 40% 1-year accuracy 2 / 5 met price target	36% upside $28	Outperform Initiated	13 Dec 2024
Morgan Stanley Tejas Savant 33% 1-year accuracy 4 / 12 met price target	12% upside $23	Equal-Weight Assumed	3 Dec 2024